Global Fibrotic Diseases Treatment Market Size, Share & Trends Analysis Report, By Treatment (Drugs, Therapy, and Surgery), By Application (Idiopathic Pulmonary Fibrosis, Cutaneous Fibrosis, Renal Fibrosis, Hepatic Cirrhosis, and Others), By End-User (Hospitals, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), Forecast (2022-2028)

The global fibrotic diseases treatment market is anticipated to grow at a CAGR of 6.0% during the forecast period (2022-2028). Fibrosis is a distinctive biochemical characteristic of majority of chronic inflammatory diseases. It is scarring that results out of the accumulation of excess extracellular matrix components. If highly progressive, the fibrotic process eventually leads to organ malfunction and mortality. The market growth is majorly attributable to the growing incidences of fibrosis and the growing R&D activities related to its therapeutics. In addition to this, the growing cases of idiopathic pulmonary fibrosis is also anticipated to spur the demand for fibrotic diseases treatment, thereby driving the market growth. Idiopathic pulmonary fibrosis is a rare and serious disease that primarily affects human lungs and leads to the building up of scar tissue within the lungs. For instance, as per the National Institutes of Health (NIH) in the US alone, about 30,000 to 40,000 new cases of idiopathic pulmonary fibrosis are found each year.

The projection of this disease is estimated to grow substantially on a global level. For instance, the new cases of this fibrosis are projected to be 10.7 cases per 100,000 person-years for males and 7.4 cases per 100,000 person-years for females across the globe. The prevalence of idiopathic pulmonary fibrosis is estimated to be 20 cases per 100,000 persons for males and 13 cases per 100,000 persons for females. Some key players operating in the market include Boehringer Ingelheim International GmbH, Genentech, Inc., and Apotex Inc., among others.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Treatment
  • By Application
  • By End-User
  • By Distribution Channel
• Regions covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape: Boehringer Ingelheim International GmbH, Genentech, Inc., and Apotex Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Fibrotic Diseases Treatment Market Report by Segment

By Treatment

• Drugs
  • Pirfenidone (Esbriet)
  • Nintedanib (OFEV)
• Therapy
• Surgery

By Application

• Idiopathic Pulmonary Fibrosis
• Cutaneous Fibrosis,
• Renal Fibrosis
• Hepatic Cirrhosis
• Others

By End-User

• Hospitals
• Specialty Clinics
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

Global Fibrotic Diseases Treatment Market Report by Region

North America

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

 

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

 

Rest of the World

• Latin America
• Middle East and Africa